Labetuzumab
From Wikipedia, the free encyclopedia
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | carcinoembryonic antigen |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 219649-07-7  |
| ATC code | None |
| KEGG | D08936  |
| Chemical data | |
| Formula | ? |
 (what is this?) (verify) |
|
Labetuzumab (marketed under the trade name CEA-CIDE) is a humanized IgG1 monoclonal antibody for the treatment of colorectal cancer.[1]
This drug was developed by Immunomedics, Inc.
[edit] References
- ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Labetuzumab, American Medical Association.
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
 |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
